Tumor microenvironment-derived miRNAs as prognostic markers of breast cancer


  • N.Yu. Lukianova R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • T.V. Borikun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology
  • V.F. Chekhun R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology




breast cancer, miRNA


Summary. Aim: To study expression of miRNA derived from tumor microenvironment in patients with breast cancer (BC) as the aspect of tumor-host interaction. Materials and Methods: The expression levels of estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2/neu) were analyzed in tissue of BC using immunohistochemical method. Relative expression levels of the miR-155, -320a, and -205 were examined in tissue and sera from BC patients using quantitative reverse transcription polymerase chain reaction. Results: Serum and tissue miR-155, -320a, and -205 levels in patients with BC are of low diagnostic value as such for differentiation of malignant and non-malignant breast neoplasms. Nevertheless, we established the relation of circulating and tissue miR-155, -320a, and -205 to lymph node metastases and basal breast cancer subtype. Conclusions: Changes of miR-155, -320a, and -205 expression in tumor tissue and sera of BC patients provide information about major clinical-pathological characteristics of BC.


Chekhun VF. The concept “tumor and host” in the post-genomic era. Exp Oncol 2005; 32: 120–4.

Berezhnaya NM, Chekhun VF. Immunology of Malignant Growth. Kyiv: Naukova Dumka, 2005. 792 p. (in Russian).

Mannello F, Medda V, Tonti GA. Protein profile analysis of the breast microenvironment to differentiate healthy women from breast cancer patients. Expert Rev Proteom 2009; 6: 43–60.

Osisami M, Keller E. Mechanisms of metastatic tumor dormancy. J Clin Med 2013; 2: 136–50.

Yu T, Di G. Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance. Chinese J Cancer Res 2017; 29: 237.

Allinen M, Beroukhim R, Cai L, et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004; 6: 17–32.

Mittal S, Brown NJ, Holen I. The breast tumor microenvironment: role in cancer development, progression and response to therapy. Expert Rev Mol Diagn 2018; 18: 227–43.

Osinsky SP. Microenvironment of cancer cells and tumor progression. Factors of stromal microenvironment. Zdoroviya Ukrainy 2013; 6: 36–9 (in Russian).

Kuninty PR, Schnittert J, Storm G, Prakash J. MicroRNA targeting to modulate tumor microenvironment. Front Oncol 2016; 6: 3.

Bell E, Taylor MA. Functional roles for exosomal microRNAs in the tumour microenvironment. Comp Struct Biotechn J 2017; 15: 8–13.

Suzuki HI, Katsura A, Matsuyama H, Miyazono K. Micro­RNA regulons in tumor microenvironment. Oncogene 2015; 34: 3085.

Bronisz A, Godlewski J, Wallace JA, et al. Reprogramming of the tumor microenvironment by stromal PTEN-regulated miR-320. Nature Cell Biol 2012; 14: 159–67.

Vosgha H, Ariana A, Smith RA, Lam AK. miR-205 targets angiogenesis and EMT concurrently in anaplastic thyroid carcinoma. Endocr Relat Cancer 2018; 25: 323–37.

Du YE, Tu G, Yang G, et al. MiR-205/YAP1 in activated fibroblasts of breast tumor promotes VEGF-independent angiogenesis through STAT3 signaling. Theranostics 2018; 7: 3972.

Mattiske S, Suetani RJ, Neilsen PM, Callen DF. The oncogenic role of miR-155 in breast cancer. Cancer Epidem Prevent Biomark 2012; 21: 1236–43.

Yang H, Yu J, Wang L, et al. miR‑320a is an independent prognostic biomarker for invasive breast cancer. Oncology Lett 2014; 8: 1043–50.

Liu J, Mao Q, Liu Y, et al. Analysis of miR-205 and miR-155 expression in the blood of breast cancer patients. Chinese J Cancer Res 2013; 25: 46.

Thike AA, Chng MJ, Tan PH, Fook-Chong S. Immunohistochemical expression of hormone receptors in invasive breast carcinoma: correlation of results of H-score with pathological parameters. Pathology 2001; 33: 21–5.

Livak K, Schmittgen T. Analysis of relative gene expression data using real–time quantitative PCR and the 2−∆∆CT method. Methods 2001; 25: 402–8.

Sun D, Zhong J, Wei W, et al. Identification of micro­RNA expression in sentinel lymph nodes from patients with breast cancer via RNA sequencing for diagnostic accuracy. J Gene Med 2019; e3075.

Zhang H, Li B, Zhao H, Chang J. The expression and clinical significance of serum miR-205 for breast cancer and its role in detection of human cancers. Int J Clin Exp Med 2015; 8: 3034.

Hu YY, Dong WD, Xu YF, et al. Elevated levels of miR-155 in blood and urine from patients with nephrolithiasis. BioMed Res Int 2014; 2014: 295651.

Bala S, Tilahun Y, Taha O, et al. Increased micro­RNA-155 expression in the serum and peripheral monocytes in chronic HCV infection. J Transl Med2012; 10: 151.

Jiang M, Zhang P, Hu G, et al. Relative expressions of miR-205-5p, miR-205-3p, and miR-21 in tissues and serum of non-small cell lung cancer patients. Mol Cell Biochem 2013; 383: 67–75.

Xu H, Yao Y, Meng, F et al. Predictive value of serum miR-10b, miR-29c, and miR-205 as promising biomarkers in esophageal squamous cell carcinoma screening. Medicine 2015; 94: 44.

Ma Q, Wan G, Wang S, et al. Serum micro­RNA-205 as a novel biomarker for cervical cancer patients. Cancer Cell Int 2014; 14: 81.

Chen J, Wang BC, Tang JH. Clinical significance of microRNA‐155 expression in human breast cancer. J Surg Oncol 2012; 106: 260–6.

Hafez MM, Hassan ZK, Zekri AR, et al. MicroRNAs and metastasis-related gene expression in Egyptian breast cancer patients. Asian Pacific journal of cancer prevention; 2012; 13: 591–8.

Nie X, Xie R, Tuo B. Effects of estrogen on the gastrointestinal tract. Digest Dis Sci 2018; 63: 583–96.

Zhuo Z, Yu H. miR-205 inhibits cell growth by targeting AKT-mTOR signaling in progesterone-resistant endometrial cancer Ishikawa cells. Oncotarget 2017; 8: 28042.




How to Cite

Lukianova, N., Borikun, T., & Chekhun, V. (2023). Tumor microenvironment-derived miRNAs as prognostic markers of breast cancer. Experimental Oncology, 41(3), 242–247. https://doi.org/10.32471/exp-oncology.2312-8852.vol-41-no-3.13615



Original contributions

Most read articles by the same author(s)

1 2 3 > >>